Karo Pharma Smart choices for everyday healthcare About Products Karo Everyday Investors News & Press English News from Karo Pharma Select year 22 November, 2021 Karo Pharma acquires Sylphar International NV for EUR 290m and intends to carry out a rights issue of approximately EUR 200-250m Karo Pharma Aktiebolag (publ) (the ”Company” or ”Karo”) has today entered into an agreement to acquire all of the shares in Sylphar International NV (“Sylphar”) and, direct and indirect, all of the shares in Pro Teeth Whitening Co Limited (“Pro Teeth Whitening”), Nutravita Limited (“Nutravita”) and Alpha Foods BV (“Alpha Foods”, together the “Sylphar Group”)... 7 September, 2021 Anna Hale appointed CMO at Karo Pharma Karo Pharma Aktiebolag (publ) (“Karo”) has appointed Anna Hale as the Chief Marketing Officer (CMO) of Karo. The appointment reflects Karo’s growth ambitions, fueled by a strategy of geographical expansion and development of its portfolio of consumer healthcare brands, plus the continuous efforts to strengthen and develop Karo’s commercial organization. 24 August, 2021 Magnus Nylén leaves Karo Pharma, Matt Roberts appointed new CCO Karo Pharma Aktiebolag (“Karo”) has appointed Matt Roberts as the new Chief Commercial Officer (CCO) of Karo, replacing Magnus Nylén who has decided to pursue opportunities outside of Karo. Matt will start his new position on September 1, 2021. “I would like to thank Magnus for his contributions at Karo. Magnus has been instrumental in... 1 July, 2021 Karo Pharma divests brand portfolio to Evolan Pharma Karo Pharma AB (“Karo”) today announces the divestment of a portfolio consisting of 12 brands to Evolan Pharma AB (“Evolan”). The transaction is effective per today, July 1[st], 2021. 6 May, 2021 Karo Pharma to sell its treasury shares Karo Pharma (“Karo”) pursues a growth strategy, which combines geographical expansion with an active acquisition strategy. To execute on this strategy, Karo needs capital and a strong financial position. The treasury shares represent an unutilized resource in the company and a sale of the shares enhances Karo’s financial flexibility. On October 30, 2020 Karo communicated... 28 April, 2021 Karo Pharma resolves on sale of own shares Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to 1,768,000 own shares to expand the company’s financial flexibility. The sale of own shares shall be effected – on one or several occasions before the 2022 Annual General Meeting, where a new mandate should be... 1 April, 2021 Karo Pharma completes the acquisition of the brand portfolio from Teva Pharmaceuticals Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for 84 MEUR, which was signed and announced on 3 February 2021, has been completed. The transaction transfers ownership of the brand portfolio, comprised of Flux ®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to... 3 February, 2021 Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m. Products Financial reports Financial Press releases Contact Karo Pharma Follow us on LinkedIn Copyright© Karo Pharma AB 2021 Cookies are required for our website to function optimally and to improve the user experience. By browsing further, you accept our use of cookies.» Privacy policy Approve